Introduction: The effectiveness of nivolumab plus ipilimumab with two cycles of chemotherapy (NIC) for advanced non-small cell lung cancer (NSCLC) has been demonstrated. We aimed to evaluate the cost-effectiveness of NIC for advanced NSCLC from the US payer perspective. Methods: A Markov model ...
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma. Nivolumab plus ipilimumab improves overall survival and is associated with less toxicity compared with sunitinib in the first-line setting of advanced rena... Bin,Qiang,Zhang,... - 《Journal for...
We evaluated the cost-effectiveness of nivolumab versus everolimus in patients with advanced renal cell carcinoma (RCC) from a US payer perspective. A partitioned survival model consisting of three health states, progression-free survival (PFS), progress
Areas covered: This is a narrative review of the published evidence on nivolumab in metastatic melanoma. Expert opinion: In ipilimumab pre-treated patients (CheckMate 037), nivolumab was associated with a higher response rate and a longer duration of response when compared to chemotherapy. In ...
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma. Nivolumab plus ipilimumab improves overall survival and is associated with less toxicity compared with sunitinib in the first-line setting of advanced rena... Bin,Qiang,Zhang,... - 《Journal for...
Here, we compared the efficacy and cost-effectiveness of nivolumab with observation or ipilimumab as adjuvant therapies in resected stage IIIB/C melanoma. ... Freeman, MorgannaBetts, Keith A.Jiang, ShanDu, Ella X.Gupte-Singh, KomalLu, YichenRao, SumatiShoushtari, Alexander N. - 《Advances ...
clinical reality to allow any conclusions of the treatments proposed. In Italy, Ipilimumab/Nivolumab received the registration only in very [select] cases, and on the basis of our analysis we are convinced that none of these treatments show any significant step forward in the fight against this ...
Latest Conference Coverage T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC Zongertinib ...
The US oncology community applauded the FDA’s approval of ipilimumab (Yervoy) in March, and the European Commission supported the use of the drug for patients with previously treated advanced melanoma among European Union member nations in July. In the United Kingdom, however, the National Instit...
One-way and probabilistic sensitivity analyses were conducted.Nivolumab-ipilimumab was the most cost-effective option in the base case analysis with an ICER of $34,190/QALY compared with sunitinib, while the pembrolizumab-axitinib ICER was dominated by nivolumab-ipilimumab and was not cost-effective ...